

status available to the public for comment. APHIS will announce the availability of this information by publishing a notice in the **Federal Register**.

(c) *Determination*. Based on the reassessment conducted in accordance with paragraph (b) of this section, including comments regarding the reassessment information, APHIS will take one of the following actions:

(1) Publish a final rule that reinstates the disease-free status of the region, or a portion of the region, covered by the interim rule;

(2) Publish an affirmation of the interim rule that imposed prohibitions or restrictions on the imports of animals and animal products from that region; or

(3) Publish another document in the **Federal Register** for comment.

Done in Washington, DC, this 19th day of June, 2003.

Bill Hawks,

Under Secretary for Marketing and Regulatory Programs.

[FR Doc. 03-15907 Filed 6-23-03; 8:45 am]

BILLING CODE 3410-34-P

NUCLEAR REGULATORY COMMISSION

10 CFR Part 63

[Docket No. PRM-63-1]

State of Nevada; Denial of a Petition for Rulemaking; Correction

AGENCY: Nuclear Regulatory Commission.

ACTION: Petition for rulemaking: denial; correction.

SUMMARY: On February 27, 2003 (68 FR 9023), the U.S. Nuclear Regulatory Commission (NRC) published a notice of denial of a petition for rulemaking. The petition for rulemaking, dated July 12, 2002, had been filed with the Commission by the State of Nevada, and assigned Docket No. PRM-63-1. The petitioner had requested that the NRC amend its regulations governing the disposal of high-level radioactive waste in a proposed geologic repository at Yucca Mountain, Nevada. This action corrects a sentence in the notice of denial by restoring a word that was mistakenly omitted from the published document. This action also corrects an erroneous citation and a typographical error in the body of the notice.

FOR FURTHER INFORMATION CONTACT: Timothy McCartin, Office of Nuclear Material Safety and Safeguards, U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001, telephone:

301-415-7285 or Toll Free: 1-800-368-5642, e-mail: tjm3@nrc.gov; or Michael T. Lesar, Office of Administration, U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001, telephone: 301-415-7163 or Toll Free: 1-800-368-5642, e-mail: MTL@nrc.gov.

SUPPLEMENTARY INFORMATION: In FR Doc. 03-4625, published on February 27, 2003 (68 FR 9023), the following corrections are made.

1. On page 9025, in the third column, the second heading is corrected to read as follows:

a. 10 CFR part 63 Is in Accord With NWPA Requirements.

2. On page 9026, in the third column, the third sentence from the bottom of the column is corrected to read as follows:

The Commission decided to reexamine its implementation of a multiple barrier approach and propose a regulation which required a system of multiple barriers, but which did not set numerical goals for the performance of individual barriers.

3. On page 9032, in the fifth line, the words "Swedish Nuclear Power Inspectorate" are replaced by the words "Swedish Nuclear Fuel and Waste Management Company".

Dated at Rockville, Maryland, this 18th day of June, 2003.

For the Nuclear Regulatory Commission.

Annette Vietti-Cook,

Secretary of the Commission.

[FR Doc. 03-15861 Filed 6-23-03; 8:45 am]

BILLING CODE 7590-01-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

21 CFR Parts 1301, 1306

[Docket No. DEA-202P]

RIN 1117-AA68

Authority for Practitioners To Dispense or Prescribe Approved Narcotic (Opioid) Controlled Substances for Maintenance or Detoxification Treatment

AGENCY: Drug Enforcement Administration (DEA), Justice.

ACTION: Notice of proposed rulemaking.

SUMMARY: DEA proposes to amend its regulations to allow qualified practitioners to dispense and prescribe to narcotic (opioid) dependent persons Schedule III, IV, and V narcotic (opioid) controlled drugs approved by the Food and Drug Administration specifically for use in maintenance or detoxification

treatment. These practitioners would not need to obtain a separate DEA registration as a narcotic treatment program to legally dispense or prescribe these drugs. Such practitioners, however, must be deemed "qualifying physicians" by the Secretary, Department of Health and Human Services. This notice of proposed rulemaking is in response to the recent amendments to the Controlled Substances Act by the Drug Addiction Treatment Act of 2000 (DATA), title XXXV of the Children's Health Act of 2000 (Pub. L. 106-310), that are designed to expand and improve treatment of opioid addiction. The proposed regulations are intended to accomplish the goals of DATA while preventing the diversion of Schedule III, IV, and V narcotic (opioid) controlled drugs approved by the Food and Drug Administration specifically for maintenance/detoxification treatment.

DATES: Written comments must be postmarked on or before September 22, 2003.

ADDRESSES: Comments should be submitted to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA **Federal Register** Representative/CCR.

FOR FURTHER INFORMATION CONTACT: Patricia M. Good, Chief, Liaison and Policy Section, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Telephone (202) 307-7297.

SUPPLEMENTARY INFORMATION:

What Change in the Current Regulations Is This Notice Proposing?

With passage of the Drug Addiction Treatment Act of 2000 (DATA), title XXXV of the Children's Health Act of 2000 (Pub. L. 106-310; 116 Stat. 1222), this notice of proposed rulemaking proposes to amend the regulations affecting maintenance and detoxification treatment for narcotic (opioid) addiction. The Controlled Substances Act (CSA) and current regulations require that practitioners who want to conduct maintenance or detoxification treatment using narcotic (opioid) controlled drugs be registered with DEA as narcotic treatment programs (NTPs) in addition to the practitioners' personal registrations. The separate NTP registrations authorize the practitioners to dispense or administer, but not prescribe, narcotic (opioid) controlled drugs.

Proposed § 1301.27 would establish an exemption from the separate registration requirement for qualified